The global leaderboard of wealth: $1.2 Quadrillion of Assets ranked by Market Cap
In-depth research + analysis available with Pro ($3.99/mo) or Pro Plus ($9.99/mo). Everything else on this page is free.
Article
Article
Article
Article
Natera's stock soared to unprecedented levels following a price target increase from analysts and promising developments in its colon cancer testing services. This article delves into the factors behind the stock's rise, the significance of its medical advancements, and the broader implications for investors and the healthcare sector. ## BODY: Natera Inc. (NTRA), a prominent player in genetic testing and diagnostics, has recently made headlines in the financial and healthcare sectors. The comp